MECHELEN, Belgium, Dec. 4, 2013 (GLOBE NEWSWIRE) -- Galapagos NV (Euronext: GLPG) announced today that GLPG1205, a first-in-class molecule for inflammatory disorders, has demonstrated target engagement, a good safety profile, and favorable drug properties in a Phase 1 study. Galapagos is developing GLPG1205 within its alliance with Janssen Pharmaceutica NV.
Help employers find you! Check out all the jobs and post your resume.
